Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot!
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope and Dr. Jonathan Kay discuss the Great Debate, which Dr. Pope participated in, at ACR22 Convergence in Philadelphia, PA.
Watch video →
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence. Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Watch video →
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at ACR22 Convergence.
Watch video →
Switch vs Cycle in PsA
Dr. Arthur Kavanaugh discusses abstract 1600 at ACR22 Convergence. Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Watch video →
New Treatments for SLE?
Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Watch video →
Best of PsA on Day 1
Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence. Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Watch video →
Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Watch video →
A Novel Treatment Response Measurement Tool for Lupus
Dr. Kathryn Dao discusses abstract 2054 with Dr. Eric Morand at the ACR22 Convergence meeting. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
Watch video →
Richard Conway RichardPAConway
3 years 10 months ago
Jayne et al. ADVOCATE avacopan trial sub-analysis looking at patients eGFR<=20. Significantly better reduction albuminuria and increase eGFR. Numerically better recovery, lower GC, less infection @RheumNow #ACR22 Abstr#0525 https://t.co/v4ffiqfsyt https://t.co/9pK0Pn6IOj
sheila RHEUMarampa
3 years 10 months ago
🔎Look! Urinary biomarkers vs. UPCR in tx response of #lupus nephritis by Dr @andreafava et al
🦋A decline in several urinary BMs at 3 mos outperformed UPCR in predicting the 1 yr response.
Urinary BMs as surrogate endpts in trials?🤔#ACR22 @RheumNow ABST0536 https://t.co/kMWmsK8mnO
Richard Conway RichardPAConway
3 years 10 months ago
@GuyKatzMD @zach_wallace_md et al. Hypocomplementemia seen in 30% IgG4-RD. More organs involved (mean 4.3 vs 2.9). More likely to have serum IgG4 above ULN (89%vs74%) and 5XULN (52%vs28%) @rheumnow #ACR22 Abstr#0144 https://t.co/bVRTuh3dsU https://t.co/3SHEbg2tbR
Richard Conway RichardPAConway
3 years 10 months ago
Sanchez-Bilbao et al. IV vs SC tocilizumab in 471 GCA patients. No differences in sustained remission or glucocorticoid-sparing. Numerically more AEs in IV but this due to longer follow up, no difference when corrected @rheumnow #ACR22 Abstr#0146 https://t.co/EB2RMYdzAr https://t.co/4xIMH1PIt3
Richard Conway RichardPAConway
3 years 10 months ago
Fussner @LynnFussner et al. DAH in PEXIVAS. DAH more freq younger, PR3+, relapsing, higher disease activity, higher creatinine. DAH more likely to die at 30 days and 1 year than those without DAH @RheumNow #ACR22 Abstr#0526 https://t.co/XGYHvDkVeA https://t.co/IEOcQHEQ3e
Dr. Rachel Tate uptoTate
3 years 10 months ago
Normal weight PsA pts had numerically better PsAID and PGA scores than obese PsA pts when treated with SEC. SEC was effective in all BMI subgroups. Abs 0395 #ACR22 @RheumNow https://t.co/oBSsuJKRem https://t.co/BhybOk76Gr
Richard Conway RichardPAConway
3 years 10 months ago
Werth et al. Lenabasum phase 3 trial indermatomyositis. Primary endpoint (TIS week 28) not met. Subgroup analysis suggest small effect on muscle and modest effect on skin disease @rheumnow #ACR22 Abstr#0173 https://t.co/qhL2PcTcHV https://t.co/uR8Bg5awiK
Richard Conway RichardPAConway
3 years 10 months ago
Vikse et al. Norwegian case series of 40 patients treated with RTX for IgG4-RD. Efficacy across phenotypes 80-100% for improvement but only 45-78% for remission. @rheumnow #ACR22 Abstr#0147 https://t.co/J7b47ywbt0 https://t.co/pfhOIG5qXk
Bella Mehta bella_mehta
3 years 10 months ago
This work can lay foundation to so much more!
#ArtificialIntelligence and #naturallanguageprocessing on Facebook private #gout groups
- Mental health mentioned in 4% of all posts/comments
- primary care asso with “trust” and urgent care with “fear”
@RheumNow #ACR22 abst#0201 https://t.co/fSuOeNGWvg
Richard Conway RichardPAConway
3 years 10 months ago
Liew @rheum_cat et al. No evidence of cardioprotective effect of early initiation of TNFi in AxSpA. In fact seemed to be associated higher risk! CVD (HR 1.17), stroke (HR 1.24), and MACE (HR 1.22) @rheumnow #ACR22 Abstr#0415 https://t.co/a9lpxQuMB9 https://t.co/GdGfYxcAH6
Richard Conway RichardPAConway
3 years 10 months ago
Germano et al. Physical exam of temporal arteries predictive of TAB+. Decreased pulse nad thickened artery most useful @rheumnow #ACR22 Abstr#0483 https://t.co/NGvu8pMiaj https://t.co/F0Y9oy0hWy
Richard Conway RichardPAConway
3 years 10 months ago
Merkel. Vilobelimab in AAV. C5a mab. Phase 2. Given with RTX/CYC. Various steroid regimes (none, reduced, standard). Not powered for non-inferiority but encouraging results. Makes sense, this is the same pathway as avacopan @RheumNow #ACR22 Abstr#0524 https://t.co/HY5i6wqnjI https://t.co/CTXUdP3PZV
Robert B Chao, MD doctorRBC
3 years 10 months ago
Exciting development in Lupus!
Change in urinary biomarkers (CD163 and MMR) better predictor than proteinuria for lupus nephritis treatment response.
Larger longitudinal studies needed.
Abs#0536
@RheumNow #ACR22
#ACRBest https://t.co/MLSWdl0xUo
Richard Conway RichardPAConway
3 years 10 months ago
Bandeira et al. When to look for cardiac involvement in IIM. Lung involvement and anti-SRP abs both ORs of >7 main warning signs @rheumnow #ACR22 Abstr#0171 https://t.co/02cKN23Ufq https://t.co/3NioXUwVPM
Akhil Sood MD AkhilSoodMD
3 years 10 months ago
Pearl - ‘Three Useful Ophthalmologic Acronyms’ with Dr. John Stone
KP- Keratic Precipitates
PUK- Peripheral Ulcerative Keratitis
IOI- Idiopathic Orbital Inflammation
Add PUK to the Rheum Emergencies. Seen in #RA and #AAV
@RheumNow #ACR22 https://t.co/GUc9boY0WV
